Developments in Antiviral Drug Design, Discovery and Development in 2004

Abstract

This article summarizes key aspects of progress made during 2004 toward the design, discovery and development of antiviral agents for clinical use. Important developments in the identification, characterization and clinical utility of inhibitors of human immunodeficiency virus; the hepatitis viruses, hepatitis B, hepatitis C; the herpes family of viruses, herpes simplex viruses 1 and 2, varicella zoster virus, Epstein-Barr virus and human cytomegalovirus; the respiratory viruses, influenza, respiratory syncytial virus, human metapneumovirus, picornaviruses, measles and the severe acute respiratory syndrome coronavirus; human papilloma virus; rotavirus; Ebola virus and West Nile virus, are reviewed.

Synthesis, Antimicrobial Activity, Anti‐HIV Activity, and Molecular Docking of Novel 5‐, 6‐ and 7‐Membered Ring (1H‐Pyrrol‐2‐yl)aminolactams

“…The scope of antiviral drugs discovery continues to be an important role of the medicinal industry's efforts for developing new agents that address significant medical needs. Twenty marketed anti‐HIV drugs are inhibitors that involve eight nucleoside reverse transcriptase inhibitors (NRTIs), eight protease inhibitors (PIs), and three non‐nucleoside reverse transcriptase inhibitors (NNRTIs) [23] . NNRTIs have acquired an important place due to their unique anti‐HIV potency with low toxicity.…”

Approaches for the Development of Antiviral Compounds: The Case of Hepatitis C Virus

“…Several excellent reviews have appeared recently (Condon et al 2005;Huang et al 2006;Meanwell et al 2005;Neyts 2006;Shim et al 2006;Wu et al 2005), which summarize the development of agents to treat HCV infection. In this report we highlight the application of modern drug discovery tools and techniques to inhibit HCV replication by describing selected examples that have appeared recently in the scientific literature.…”